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Abstract
Background: Neuroblastoma is a frequently lethal pediatric cancer in which MYCN genomic
amplification is highly correlated with aggressive disease. Deregulated MYC genes require co-
operative lesions to foster tumourigenesis and both direct and indirect evidence support activated
Ras signaling for this purpose in many cancers. Yet Ras genes and Braf, while often activated in
cancer cells, are infrequent targets for activation in neuroblastoma. Recently, the Ras effector
PIK3CA was shown to be activated in diverse human cancers. We therefore assessed PIK3CA for
mutation in human neuroblastomas, as well as in neuroblastomas arising in transgenic mice with
MYCN overexpressed in neural-crest tissues. In this murine model we additionally surveyed for Ras
family and Braf mutations as these have not been previously reported.
Methods: Sixty-nine human neuroblastomas (42 primary tumors and 27 cell lines) were sequenced
for PIK3CA activating mutations within the C2, helical and kinase domain "hot spots" where 80% of
mutations cluster. Constitutional DNA was sequenced in cases with confirmed alterations to assess
for germline or somatic acquisition. Additionally, Ras family members (Hras1, Kras2 and Nras) and
the downstream effectors Pik3ca  and Braf, were sequenced from twenty-five neuroblastomas
arising in neuroblastoma-prone transgenic mice.
Results: We identified mutations in the PIK3CA gene in 2 of 69 human neuroblastomas (2.9%).
Neither mutation (R524M and E982D) has been studied to date for effects on lipid kinase activity.
Though both occurred in tumors with MYCN amplification the overall rate of PIK3CA mutations in
MYCN  amplified and single-copy tumors did not differ appreciably (2 of 31 versus 0 of 38,
respectively). Further, no activating mutations were identified in a survey of Ras signal transduction
genes (including Hras1, Kras2, Nras, Pik3ca, or Braf genes) in twenty-five neuroblastic tumors arising
in the MYCN-initiated transgenic mouse model.
Conclusion: These data suggest that activating mutations in the Ras/Raf-MAPK/PI3K signaling
cascades occur infrequently in neuroblastoma. Further, despite compelling evidence for MYC and
RAS  cooperation in vitro and in vivo to promote tumourigenesis, activation of RAS  signal
transduction does not constitute a preferred secondary pathway in neuroblastomas with MYCN
deregulation in either human tumors or murine models.
Published: 05 July 2006
BMC Cancer 2006, 6:177 doi:10.1186/1471-2407-6-177
Received: 24 April 2006
Accepted: 05 July 2006
This article is available from: http://www.biomedcentral.com/1471-2407/6/177
© 2006 Dam et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2006, 6:177 http://www.biomedcentral.com/1471-2407/6/177
Page 2 of 10
(page number not for citation purposes)
Background
Neuroblastoma is a common childhood tumor arising
from neural crest-derived cells of the sympathetic nervous
system. It is one of the most extensively characterized
solid tumors at the genomic level and provides the para-
digm for the clinical utility of genomic alterations in
defining tumor phenotype. Much of the clinical heteroge-
neity seen with this tumor (spanning spontaneous regres-
sion to relentless disease progression) can be attributed to
distinct tumor-specific genetic alterations that correlate
strongly with disease course. These include genomic loss
within 1 p and 11 q, and gain of 17 q, among others. Still,
little is known about the genes or cellular processes tar-
geted by the majority of these genomic changes. Key regu-
latory genes frequently targeted for activation or
inactivation in a plethora of adult human cancers (e.g.,
Ras, TP53, CDKN2A, RB1) are rarely, if ever, mutated in
neuroblastoma. The sole exception to this is the MYCN
proto-oncogene, which is markedly amplified and overex-
pressed in ~22% of neuroblastomas and independently
correlates with advanced disease and adverse outcome
[1,2].
Deregulated expression of MYC genes, including MYCN,
inhibits cellular differentiation and promotes mitogen-
independent proliferation [3]. However, sensitivity to
apoptotic stressors is concurrently enhanced as a safe-
guard against neoplastic transformation, and therefore
oncogenesis mediated by MYC genes requires co-operat-
ing lesions that either disable the MYC-death signaling
axis [4,5] or repress it through constitutive survival sig-
nals. We are interested in defining these co-operating
lesions, in addition to identifying oncogenic lesions that
contribute to neuroblastoma tumourigenesis or progres-
sion independent of MYCN. Activating mutations in Ras
family genes have been identified in 30% of human can-
cers [6]. Activated Ras (1) co-operates with MYC to trans-
form primary cells in vitro and promote tumourigenesis
in vivo [7]; (2) regulates myriad cellular processes includ-
ing survival; and (3) acts to stabilize Myc proteins through
post-translational modifications [8,9]. These data strongly
support this pivotal pathway as a candidate for aberrant
activation in human neuroblastoma, and specifically in
co-operating with MYCN in tumors with MYCN amplifi-
cation or deregulated expression.
Still, activating mutations have rarely been identified in
HRAS1, KRAS2 or NRAS in human neuroblastoma [10-
12]. Occasional Ras effector alterations have been identi-
fied but collectively they are infrequent. These include
biallelic inactivation of NF1 and mutations in the Noo-
nan-associated SHP2/PTPN11 gene [13-16]. Downstream
of Ras are multiple signal transduction pathways respon-
sible for the execution of Ras-mediated cellular effects
[17] and cell-type and species specificity for transforma-
tion has been noted [18]. The most widely validated as
contributing to human tumorigenesis include the Raf-
MAPK and phosphatidylinositol 3-kinase (PI3K) path-
ways [19,20]. Somatic activating mutations have been
identified in multiple human cancers within these path-
ways, particularly in the BRAF and PIK3CA genes, respec-
tively [21,22]. Activated PI3K signaling has been proposed
to foster Myc/Ras co-operativity through Akt-mediated
phosphorylation of FoxO transcription factors [23] to de-
represses MYC target genes, and activated PI3K genes pro-
tect against Myc induced cell death sensitivity [24]. These
Ras effector signaling components have not been studied
in neuroblastoma. As PIK3CA has been shown to be acti-
vated through somatic mutation in >25% of colorectal,
breast and ovarian carcinomas, as well as in human CNS
tumors (including anaplastic oligodendrogliomas, gliob-
lastoma multiforme and medulloblastoma), we hypothe-
sized that PIK3CA mutations may substitute for activating
RAS lesions in neuroblastoma tumourigenesis. Therefore,
we performed a targeted sequencing analysis of the
PIK3CA gene in primary neuroblastomas and neuroblast-
oma-derived cell lines.
To further explore Raf-MAPK and PI3K signaling in neu-
roblastic tumors we evaluated tumors arising in neurob-
lastoma-prone genetically engineered mice (GEM). In this
model human MYCN gene overexpression is targeted to
neural crest tissues using the rat tyrosine hydroxylase pro-
moter [25]. Neuroblastic tumors arise stochastically
within the sympathetic ganglia with near-complete pene-
trance. These tumors are genomically complex with chro-
mosomal gains and losses at regions orthologous to
regions similarly altered in human neuroblastoma
[26,27]. Thus, the model faithfully recapitulates the
human condition with deregulated MYCN as the initiat-
ing event biologically and genetically [25-27]. To deter-
mine whether alterations in Ras/Raf/PIK signaling were
co-operating with MYCN  in this model we sequenced
Hras1, Kras2, Nras, Braf and Pik3ca to assess for activating
mutations as these genes and pathways have not been
studied previously using this model.
Methods
Human neuroblastoma specimens
Forty-two (42) primary neuroblastoma-derived DNA
specimens were acquired from the Children's Oncology
Group (COG; Arcadia, CA) for PIK3CA sequence analysis.
Constitutional DNA samples were subsequently obtained
from the COG Nucleic Acids bank for two patients with
tumors demonstrating PIK3CA  sequence alterations to
determine whether these were tumor-specific (somatic) or
germ line in origin. These studies were approved by the
Institutional Review Board at The Children's Hospital of
Philadelphia. Twenty-seven (27) additional neuroblast-
oma cell line DNA specimens, obtained from The Chil-BMC Cancer 2006, 6:177 http://www.biomedcentral.com/1471-2407/6/177
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dren's Hospital of Philadelphia cell line bank and the
Wellcome Trust Sanger Institute and reported previously
[28,29], were similarly investigated for PIK3CA  muta-
tions.
Murine neuroblastoma specimens
Twenty-five (25) tumors were harvested from genetically
engineered mice overexpressing human MYCN in neural-
crest tissues under the rat tyrosine-hydroxylase promoter
[TH-MYCN GEM model] [25]. In this model, tumors arise
stochastically within the peripheral sympathetic nervous
system (in the retroperitoneum or posterior thorax) with
near-complete penetrance in mice homozygous for the
MYCN transgene. Founders for establishment of the TH-
MYCN GEM colony at The Children's Hospital of Phila-
delphia were generously provided by Dr. William Weiss
(UCSF). Ten tumors in this study came from early back-
crosses (received from UCSF) and fifteen additional
tumors came from animals backcrossed to homozygosity
in the 129X1/SvJ background. Tumors were flash frozen at
necropsy and partitioned for subsequent DNA and RNA
extraction using the DNeasy and RNeasy Midi Tissue kits,
respectively, according to the manufacturer's instructions
(Qiagen; Valencia, CA). All mouse experiments were
approved by the Institutional Animal Care and Use Com-
mittee (IACUC) at The Children's Hospital of Philadel-
phia.
Candidate gene sequencing: human PIK3CA
Primer pairs that amplify exons 4, 5, 9 and 20 of the
PIK3CA gene in human tumors were synthesized (Inte-
grated DNA Technologies, Inc., Coralville, 1A). These
exons encode the C2, helical, and kinase domains, respec-
tively, which demonstrate high rates of somatic mutation
in human cancers [22]. The four primer pairs used to
amplify exons 5, 9 and 20 from genomic DNA were iden-
tical to those used by Samuels, et al. [22]. Primers that
amplify exon 4 were designed using Primer 3 software
http://frodo.wi.mit.edu: HumPIK3CA-ex4-F1, 5'-TCT TGT
GCT TCA ACG TAA ATC C-3', and HumPIK3CA-ex4-R1,
5'-CGG AGA TTT GGA TGT TCT CC-3'. PCR amplification
with each pair yielded a single specific band of appropri-
ate size using control genomic DNA input.
Murine Pik3ca
Primer pairs that amplify exons 9 and 20 (helical and
kinase domains, respectively) were designed using Primer
3 software and Pik3ca  sequence (accession no. Gen-
Bank:XM355754). These were: (1) MurPIK3CA-ex9-F1,
5'-CCA AGG AAA TCA TGG CAG AG-3', and MurPIK3CA-
ex9-R1, 5'-TGT CCC TGA CAG GAA GAA GG-3'; and (2)
MurPIK3CA-ex20-F1, 5'-GCA GCT CAC TGA CCA GAT
GT-3', and MurPIK3CA-ex20-R1, 5'-ACT GCC ATG CAG
TGG AGA A-3'. Amplification of genomic DNA (control)
yielded appropriate single products of 240 and 358 base
pairs, respectively.
Murine Ras/Raf pathway genes
Primer sequences to amplify the entire coding region of
murine  Hras1  (GenBank:NM008284),  Kras2  (Gen-
Bank:NM021284), and Nras (GenBank:NM010937) from
cDNA were kindly provided by Lewis Chodosh (Univer-
sity of Pennsylvania). These are: (1) mHRAS1-F1-seq, 5'-
AGA ATA CAA GCT TGT GGT GGT GG-3', and mHRAS1-
R1-seq, 5'-CCT GTA CTG ATG GAT GTC CTC G-3'; (2)
mKRAS2-F1-seq, 5'-GTA AGG CCT GCT GAA AAT G-3',
and mKRAS2-R1-seq, 5'-GGT GAA TAT CTT CAA ATG AT-
3'; and (3) mNRAS-F1-seq, 5'-GGT CTC CAA CAG CTC
AGG TTG AAG-3', and mNRAS-R1-seq, 5'-GTA CCT GTA
GAG GTT AAT ATC TGC A-3'. Primers to amplify the ser-
ine/threonine kinase domain of Braf (XM355754) were
designed using Primer 3 software, and were: mBRAF-F2,
5'-GAA TGT GAC AGC ACC CAC AC-3', and mBRAF-R1,
5'-CGG GTT TTT ATC TTG CAT TC-3'. All primer pairs
amplified a single reaction product of predicted size from
control cDNA.
PCR amplification, sequencing and mutation detection
Two PCR reactions were carried out for each sequencing
reaction in a final volume of 20 μl. The reaction mixture
consisted of 5 μl stock Master Mix (16 ml TaqGold Buffer
II, 9.6 ml 25 mM MgCl2, 5.2 ml 2% Ficoll, 200 μl 0.025%
Bromophenol Blue, 1.6 ml 10 nM dNTP Mix, and 7.4 ml
ddH2O), 0.4 μl 20 μM Forward-primer, 0.4 μl 20 μM
Reverse-primer, 13.0 μl sterile PCR-grade water, 0.2 μl
TaqGold DNA Polymerase (Promega Corporation, Madi-
son, Wl), and 1.0 μl sample template. For sequencing
f r o m  D N A ,  8 0  n g  w e r e  u s e d  a s  t e m p l a t e  i n p u t .  F o r
sequencing from cDNA, 2 μg RNA was reverse-transcribed
in a final volume of 20 μl with the oligodeoxythymidylic
acid primer using the Superscript II pre-amplification sys-
tem according to the manufacturer's instructions (Life
Technologies, Gaithersburg, MD). One μl of reverse tran-
scribed cDNA was used as a template. The following PCR
protocol was utilized for each sample and carried out in a
Programmable Thermal Controller-100 (MJ Research,
Inc., Waltham, MA): (1) 94°C × 12 minutes (polymerase
activation), (2) thirty DNA polymerization cycles of 94°C
× 45 seconds, 55°C × 45 seconds, 72°C × 45 seconds, fol-
lowed by 72°C × 10 minutes and 4°C holding tempera-
ture. The individual PCR amplifications for each reaction
were combined and electrophoresed through a 1% agar-
ose gel in 1× TBE buffer for 40 minutes at 90 V. The PCR
product was verified as a single specific band of predicted
size then extracted and purified using the QIAQuick Gel
Extraction Kit (Qiagen Inc., Valencia, CA).
All amplification products were sequenced bi-direction-
ally in an automatic sequencer (Applied Biosystems, Fos-BMC Cancer 2006, 6:177 http://www.biomedcentral.com/1471-2407/6/177
Page 4 of 10
(page number not for citation purposes)
ter, CA) using the primary forward and reverse primers.
This provided at least double coverage of all evaluated
sequence in each tumor sample. Sequence analysis was
carried out using Sequencher version 4.1.4 (Gene Codes
Corporation, Ann Arbor, MI) in addition to a manual
chromatogram review. Confirmatory resequencing from
replicate PCR amplification reactions was performed for
any sequence that was ambiguous or deviated from wild-
type so that all abnormal sequences were confirmed in at
least quadruplicate from replicate amplification reactions.
Results and discussion
PIK3CA mutation screening in human neuroblastoma
We screened 69 human neuroblastomas (42 primary
tumors and 27 neuroblastoma-derived cell lines) for
PIK3CA  gene mutations within exons 4, 5, 9 and 20
(Tables 1 and 2). PIK3CA is one of the most commonly
mutated oncogenes in human cancers, occurring at high
prevalence in tumors of the colon, breast, ovary, stomach
and liver, and at lower prevalence in multiple other cancer
types. Exons 9 and 20 encode portions of the helical and
kinase domains, respectively, that ~80% of previously
reported PIK3CA mutations cluster within [22,30]. These
regions encode critical domains mediating lipid kinase
activity [31]. Exons 4 and 5 encode the C2 region of the
protein (calcium-dependent phospholipid binding
domain) that is mutated in an additional ~5% of tumors,
yet this region accounts for 50% of mutations reported in
glioblastoma multiforme, a highly malignant neural
tumor [22], so we included it in our neuroblastoma inves-
tigations (Figure 1).
Overall, PIK3CA mutations were infrequently found, with
non-synonymous coding sequence alterations being iden-
tified in 2 of 69 specimens (2.9%). An additional 16
tumors had sequence alterations identified in non-coding
regions (including three specific alterations in introns and
one in the 3'-untranslated region). Of the coding
sequence mutations, one was identified within the helical
domain encoded within exon 9, occurring in the MYCN
amplified neuroblastoma cell line NLF. This heterozygous
missense mutation (G to T) results in an arginine to
methionine substitution (R524M). This mutation has not
to our knowledge been reported previously and is of
undetermined functional significance. No constitutional
nor primary tumor DNA was available from the patient
the cell line was derived from so it could not be directly
confirmed that this was a somatic mutation, nor whether
the mutation occurred in vivo or ex vivo during the course
of tissue culture propagation. The second mutation was
identified within the kinase domain (Figure 2A). This was
a heterozygous G to T alteration leading to a glutamic acid
to aspartic acid substitution (E982D) in primary tumor
#1070 (INSS stage 3, MYCN amplified). Constitutional
DNA from this individual was wild-type, confirming the
kinase domain mutation to be tumor-specific (somatic).
This specific mutation has not been previously described
nor functionally characterized to date, although an E982K
mutation has been found in anaplastic thryroid carci-
noma [32].
In addition, four unique sequence alterations were identi-
fied in at least one specimen each in non-coding regions:
two within intron 8 (C19339T and G19361A [nucleotide
number refers to position in genomic sequence relative to
the first nucleotide of exon 1]), one within intron 9
(T19623G), and one within the 3'-UTR (heterozygous
T35577C). These were identified in 5 (7.2%), 1 (1.4%), 9
(13%) and 1 (1.4%) sample, respectively. The 3'-UTR
alteration was identified in primary tumor #1218. Consti-
tutional DNA from this patient was sequenced and dem-
onstrated the same alteration, suggesting this represents a
polymorphic variant (Figure 2B). None of these altera-
tions appears to disrupt splice donor or acceptor sites.
However, none of these alterations represents a previously
identified SNP based on a query of the dbSNP (build 125;
http://www.ncbi.nlm.nih.gov). Finally, no mutations
were identified within exons 4 or 5 within the C2 domain
in any neuroblastoma tissue.
Thus, PIK3CA, like RAS genes, is an infrequent target for
activating mutation in neuroblastoma. In our series of 69
human neuroblastomas, amino acid sequence alterations
were identified in only two (one in a MYCN amplified cell
line, and one in a MYCN amplified INSS stage 3 tumor),
albeit in a survey restricted to domain "hotspots" (C2, hel-
ical, kinase) that harbor >80% of mutations identified to
date [22]. Although these alterations occur within regions
where mutations cluster, it is not known whether they
augment lipid kinase activity and are functionally signifi-
cant. Still, we did not identify any synonymous sequence
alterations in the coding regions assessed so random non-
selected alterations are infrequent. Of note, these findings
are consistent with similar low frequencies of mutation
(<5%) in other embryonal malignancies such as medul-
loblastoma [33] and leukemia/lymphomas [30], in con-
trast to the higher prevalence of mutations in many adult
epithelial cancers. The prevalence of PIK3CA mutations in
other pediatric cancers has not yet been reported.
Assessment of the Ras, Raf, PI3K pathway in murine 
neuroblastomas arising in the TH-MYCN genetically 
engineered mouse (GEM)
Neuroblastomas arise with near-complete penetrance in
TH-MYCN GEM homozygous for the transgene. Tumors
develop focally in the peripheral nervous system and
demonstrate genomic complexity with high similarity to
human neuroblastomas [26]. For this reason, we used this
model to determine whether Ras, Raf and/or Pi3k signal-
ing constituted a preferred secondary pathway withBMC Cancer 2006, 6:177 http://www.biomedcentral.com/1471-2407/6/177
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Table 1: PIK3CA in Primary Human Neuroblastomas
Primary NB Age (mos.) INSS stage MYCN Tumor PIK3CA sta-
tus*
Constitutional 
PIK3CA status
#1347 1.4 1 S wt (het. G19361A; 
intron 8)
-
#1354 10.5 1 S wt -
#1344 11.7 1 S wt -
#1260 13.5 1 S wt -
#1308 23.2 1 S wt -
#1334 25.5 1 S wt (het. T19623G; 
intron 9)
-
#1127 52.8 1 S wt -
#354 71.9 1 AMP wt (het. C19339T; 
intron 8)
-
#1248 2.3 2 S wt -
#1087 16.4 2 S wt -
#1142 48.7 2 S wt -
#1281 82.9 2 S wt -
#190 104.0 2 AMP wt -
#1330 20.0 2 S wt -
#1339 50.0 2 S wt -
#0157 178.1 2 AMP wt (het. C19339T; 
intron 8)
-
#1137 4.5 3 AMP wt -
#1290 7.9 3 S wt -
#1345 12.2 3 S wt -
#1258 21.1 3 S wt -
#1070 23.4 3 AMP E982D (+het. 
C19339T; intron 8)
wt (+het. C19339T; 
intron 8)
#1223 35.8 3 AMP wt -
#1289 2.5 4 S wt -
#1302 2.6 4 S wt (het. T19623G; 
intron 9)
-
#1259 3.2 4 S wt (het. C19339T; 
intron 8)
-
#1066 6.7 4 AMP wt (het. C19339T; 
intron 8)
-
#1304 8.9 4 S wt -
#1068 13.5 4 AMP wt -
#1243 19.2 4 AMP wt -
#1266 23.3 4 AMP wt -
#1198 24.0 4 AMP wt -
#1287 24.9 4 AMP wt (het. T19623G; 
intron 9)
-
#1210 33.4 4 S wt -
#1204 36.8 4 S wt -
#1218 37.8 4 S wt (het. T35577C in 
3'-UTR)
wt (het. T35577C in 
3'-UTR)
#1213 40.5 4 S wt -
#1263 40.7 4 AMP wt -
#1236 46.3 4 S wt -
#1337 50.0 4 S wt -
#1246 52.1 4 AMP wt -
#1288 54.2 4 AMP wt (het. T19623G; 
intron 9)
-
#1220 60.3 4 S wt -
INSS; International Neuroblastoma Staging System.
AMP; MYCN genomic amplification.
S; single-copy MYCN per haploid genome.
wt; wild-type sequence
* Nucleotide position referenced from genomic sequence 1st nucleotide of exon 1.BMC Cancer 2006, 6:177 http://www.biomedcentral.com/1471-2407/6/177
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MYCN deregulation. To assess for activating mutations in
Pi3kca  we sequenced the helical and kinase encoding
regions (exons 9 and 20) from 25 neuroblastomas har-
vested from heterozygous or homozygous transgene car-
rying mice. All 25 murine neuroblastomas harbored wild-
type Pik3ca sequence (Table 3).
We next assessed genes in the Ras and Raf pathway in
these same 25 murine neuroblastomas, including Hras1,
Kras2,  Nras  and  Braf, which are frequently mutated in
human cancers and in MYC-initiated murine tumor mod-
els [34]. No non-synonymous sequence alterations were
identified in these genes. One tumor (THMYCN-21) had
three synonymous alterations identified: one each in the
Hras1, Kras2 and Nras genes. One additional synonymous
alterations was identified in THMYCN-17 in Kras2 (Table
3). These findings likely represent polymorphic variants
and were found only in tumors from early mice back-
crosses predicted to harbor strain specific polymorphisms.
Tumors harvested following extensive backcrossing to
homozygosity had no non-synonymous alterations iden-
tified. The low frequency of Pik3ca, Ras family, and Braf
activating mutations in tumors arising in the TH-MYCN
GEM supports that activated Ras-mediated signal trans-
duction is not a pre-requisite for neuroblastoma develop-
ment in concert with deregulated MYCN in this model. In
this respect the GEM model is consistent with the human
tumor.
Conclusion
Pik3ca, Ras family, and Braf activating mutations occur
rarely in human neuroblastomas or in a murine model
driven by neural-restricted MYCN overexpression. These
data support that activated Ras-mediated signal transduc-
tion does not constitute a preferred secondary pathway for
neuroblastic tumors in concert with deregulated MYCN.
Table 2: PIK3CA in Neuroblastoma cell lines
NB Cell Line MYCN Exon 4 Exon 5 Exon 9 Exon 20
L A - N - 1 A M P w tw tw tw t
S K - N - B E 2 A M P w tw tw tw t
SK-N-SH S wt wt wt wt
NB-69 S wt wt wt wt
SK-N-DZ AMP wt wt wt wt
SMS-KCN AMP wt wt wt wt
SY5Y S wt wt wt (T19623G; intron 
9)
wt
C H P 1 3 4 A M P w tw tw tw t
C H P 1 2 6 A M P w tw tw tw t
C H L A - 1 5 0 S w tw tw tw t
NGP AMP wt wt wt wt
SMS-KAN AMP wt wt wt (T19623G; intron 
9)
wt
I M R 5 A M P w tw tw tw t
NMB AMP wt wt wt (T19623G; intron 
9)
wt
SK-N-AS S wt wt wt wt
LA-N-6 (OAN) S wt wt wt wt
CHLA-79 S wt wt wt (T19623G; intron 
9)
wt
IMR32 AMP wt wt wt wt
N B 1 6 S w tw tw tw t
SK-N-FI S wt wt wt (T19623G; intron 
9)
wt
NBL-S S wt wt wt wt
C H P 9 0 1 A M P w tw tw tw t
C H L A - 1 7 1 S w tw tw tw t
SMS-KCNR AMP wt wt wt wt
SMS-SAN AMP wt wt wt wt
C H L A - 1 2 3 A M P w tw tw tw t
NLF AMP wt wt G>T/G; Het. 
R524M
wt
wt; wild-type sequence.
AMP; MYCN amplified.
S; MYCN single-copy per haploid genome.
* Position referenced from genomic sequence 1st nucleotide of exon 1.BMC Cancer 2006, 6:177 http://www.biomedcentral.com/1471-2407/6/177
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This despite the potent cooperation between Myc and acti-
vated  Ras  genes demonstrable in vitro and in vivo to
induce transformation and/or tumorigenicity. Further,
these tumor promoting pathways are rarely targeted inde-
pendent of MYCN deregulation as demonstrated by the
absence of activating lesions in neuroblastoma tumors
and cell lines without MYCN amplification. Tumor induc-
tion through activation of Ras/Raf-MAPK/PI3K pathways
clearly demonstrates cell-type specificity. For example,
studies have demonstrated epithelial cell proliferation
Detection of PIK3CA mutations Figure 2
Detection of PIK3CA mutations. Chromatogram tracing for exon 20 sequences encoding the catalytic kinase domain in pri-
mary neuroblastomas #1070 (A) and #1218 (B). Sequences demonstrate heterozygous alterations in these tumor samples as 
depicted by the arrows, with the amino acid change for #1070 being GAG (glutamic acid) to GAT (representing GAU, aspartic 
acid). Alterations were confirmed bi-directionally and in replicate sequencing. T, tumor DNA sequence; N, normal (or consti-
tutional) DNA sequence. Note the tumor-specific (somatic) mutation in #1070, whereas the alteration in the 3'-UTR in #1218 
is present in both tumor and constitutional DNA and likely represents a rare polymorphic variant.
#1070 (T)
#1070 (N)
Forward
Forward
Reverse
Reverse
Reverse
Forward
Forward
#1218 (N)
#1218 (T)
A.
B.
PIK3CA structure Figure 1
PIK3CA structure. Schematic diagram of Pik3ca protein illustrating functional domains and mutations (grouped by domain) 
reported to date [22, 30, 32, 33, 40, 41]. Codons with frequent missense mutations reported ('hotspots') are denoted by aster-
isks. Location of experimentally found mutations in this study are denoted in boldface. p85, PI3K p85 regulatory subunit binding 
domain; RBD, Ras binding domain; C2, calcium-dependent phospholipid-binding domain; Helical, PI3K helical domain; Kinase, 
PI3/4-kinase domain.
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being augmented by Ras activation while mesenchymal
cells (e.g., fibroblasts) demonstrate growth inhibition
[35]. This specificity may underscore the variable fre-
quency of Ras pathway mutation selection across cancers
and partly explain the paucity of activating mutations
found in non-epithelial embryonal malignancies such as
neuroblastoma.
However, it remains strictly possible that activating muta-
tions in alternative Ras  signaling constituents occur in
neuroblastoma. Less studied family members such as
MRAS [36] and RRAS [37] have oncogenic potential in
mammalian cells and the former demonstrates restricted
expression to neural tissues. These have not been investi-
gated in neuroblastoma although both are expressed in
primary neuroblastomas at the mRNA level (data not
shown). In distinction to activating point mutations,
pathway activation through PIK3CA gene dosage effects
following low level genomic amplification have also been
described [38]. However, these appear predominantly in
those epithelial carcinomas (breast, ovarian, gastric carci-
noma) in which activating mutations occur at higher fre-
quency as well. In contrast, gain of 3q26 including the
PIK3CA locus is infrequently reported in neuroblastoma
cells, including in those cell lines studied herein [28].
Finally, additional effector arms to Ras-mediated signal-
ing may play a role in tumourigenesis. These include
Tiam-1, RalGDS, RASSF and others (reviewed in [17]).
RASSF1A has been shown to be epigenetically silenced in
a significant proportion of high-risk neuroblastomas [39]
and elimination of this potentially pro-apoptotic pathway
may be more critical than activation of proliferative or sur-
vival signaling in the establishment of embryonal cancers.
Alternatively, Ras independent secondary pathways may
be preferentially co-opted in neuroblastoma tumor initia-
tion. These pathways remain elusive but certainly warrant
further investigation, as defining the preferred pathways
deregulated in neuroblastoma might provide suitable
novel targets for directed therapies against this frequently
lethal tumor.
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Table 3: Ras family, Braf and PIK3CA in Murine Neuroblastomas
TH-MYCN NB* MYCN** Hras1 Kras2 Nras Braf PIK3CA
1 +++ wt wt wt wt wt
2 +++ wt wt wt wt wt
3 +++ wt wt wt wt wt
4 +++ wt wt wt wt wt
5 +++ wt wt wt wt wt
6 +++ wt wt wt wt wt
7 +++ wt wt wt wt wt
8 +++ wt wt wt wt wt
9 +++ wt wt wt wt wt
10 +++ wt wt wt wt wt
11 +++ wt wt wt wt wt
12 +++ wt wt wt wt wt
13 +++ wt wt wt wt wt
14 +++ wt wt wt wt wt
15 +++ wt wt wt wt wt
16 +++ wt wt wt wt wt
17 +++ wt Y32Y wt wt wt
18 +++ wt wt wt wt wt
19 +++ wt wt wt wt wt
20 +++ wt wt wt wt wt
21 +++ S65S Y32Y A18A wt wt
22T +++ wt wt wt wt wt
23T +++ wt wt wt wt wt
24T +++ wt wt wt wt wt
25 +++ wt wt wt wt wt
wt; wild-type sequence.
* T denotes thoracic tumor (all others are retroperitoneal/abdominal).
** MYCN transgene overexpressed in neural crest tissues.BMC Cancer 2006, 6:177 http://www.biomedcentral.com/1471-2407/6/177
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